publication . Article . 2006

Efficacy and tolerability of high dose "ethinylestradiol" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents

Robertson John FR; Agrawal Amit; Cheung KL;
Open Access English
  • Published: 01 Jul 2006 Journal: World Journal of Surgical Oncology, volume 4, pages 44-44 (issn: 1477-7819, eissn: 1477-7819, Copyright policy)
  • Publisher: BioMed Central
Abstract
<p>Abstract</p> <p>Background</p> <p>High dose estrogens (HDEs) were frequently used as endocrine agents prior to the introduction of tamoxifen which carries fewer side effects. Due to the development of resistance to available endocrine agents in almost all women with metastatic breast cancer, interest has renewed in the use of HDEs as yet another endocrine option that may have activity. We report our experience with one of the HDEs ("ethinylestradiol" 1 mg daily) in advanced breast cancer (locally advanced and metastatic) in post-menopausal women who had progressed on multiple endocrine agents.</p> <p>Patients and methods</p> <p>According to a database of adva...
Subjects
free text keywords: RC254-282, RD1-811, Research, Surgery, Neoplasms. Tumors. Oncology. Including cancer and carcinogens
18 references, page 1 of 2

Lonning, PE, Taylor, PD, A., H. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy.. Breast Cancer Res Treat. 2001; 67: 111-116 [PubMed] [DOI]

KL, C. High dose oestrogen (HDE) as an endocrine therapy option for advanced breast cancer (ABC). Eur J Cancer. 2005; 37: 8

Hayward, JL, Carbone, PP, Heuson, JC. Assessment of response to therapy in advanced breast cancer . Cancer. 1977; 39: 1289-1293 [OpenAIRE] [PubMed] [DOI]

British Breast Group, . Assessment of response to treatment in advanced breast cancer. Lancet. 1974; 2: 38-39 [PubMed] [DOI]

Robertson, JFR, Willsher, PC, Cheung, KL, Blamey, RW. The clinical relevance of static disease ( no change) category for 6 months on endocrine therapy in patients with breast cancer. European Journal of Cancer. 1997; 33: 1774-1779 [PubMed] [DOI]

Cole, MP, Jones, CT, Todd, ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. . Br J Cancer. 1971; 25: 270-275 [OpenAIRE] [PubMed]

Heuson, JC, Engelsman, E, Blonk-Van Der Wijst, J, Maass, H, Drochmans, A, Michel, J, Nowakowski, H, Gorins, A. Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study. Br Med J. 1975; 2: 711-713 [OpenAIRE] [PubMed]

Massidda, B, Mascia, V, Broccia, G, Pasqualucci, S, Deplano, W, Desogus, A, Luxi, G, Pellegrini, A. [Estrogen therapy of advanced breast cancer]. Minerva Med. 1977; 68: 2509-2516 [PubMed]

Beex, L, Pieters, G, Smals, A, Koenders, A, Benraad, T, Kloppenborg, P. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rep. 1981; 65: 179-185 [PubMed]

Ingle, JN, Ahmann, DL, Green, SJ, Edmonson, JH, Bisel, HF, Kvols, LK, Nichols, WC, Creagan, ET, Hahn, RG, Rubin, J, S., F. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer.. N Engl J Med. 1981; 304: 16-21 [PubMed]

Peethambaram, PP, Ingle, JN, Suman, VJ, Hartmann, LC, CL., L. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis.. Breast Cancer Res Treat. 1999; 54: 117-122 [PubMed] [DOI]

Ingle, JN. Estrogen as therapy for breast cancer. Breast Cancer Res. 2002; 4: 133-136 [OpenAIRE] [PubMed] [DOI]

Robertson, JF, Come, SE, Jones, SE, Beex, L, Kaufmann, M, Makris, A, Nortier, JW, Possinger, K, Rutqvist, LE. Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer. 2005; 41: 346-356 [PubMed] [DOI]

Masamura, S, Santner, SJ, Heitjan, DF, Santen, RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab. 1995; 80: 2918-2925 [PubMed] [DOI]

Osipo, C, Gajdos, C, Cheng, D, Jordan, VC. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol. 2005; 93: 249-256 [PubMed] [DOI]

18 references, page 1 of 2
Abstract
<p>Abstract</p> <p>Background</p> <p>High dose estrogens (HDEs) were frequently used as endocrine agents prior to the introduction of tamoxifen which carries fewer side effects. Due to the development of resistance to available endocrine agents in almost all women with metastatic breast cancer, interest has renewed in the use of HDEs as yet another endocrine option that may have activity. We report our experience with one of the HDEs ("ethinylestradiol" 1 mg daily) in advanced breast cancer (locally advanced and metastatic) in post-menopausal women who had progressed on multiple endocrine agents.</p> <p>Patients and methods</p> <p>According to a database of adva...
Subjects
free text keywords: RC254-282, RD1-811, Research, Surgery, Neoplasms. Tumors. Oncology. Including cancer and carcinogens
18 references, page 1 of 2

Lonning, PE, Taylor, PD, A., H. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy.. Breast Cancer Res Treat. 2001; 67: 111-116 [PubMed] [DOI]

KL, C. High dose oestrogen (HDE) as an endocrine therapy option for advanced breast cancer (ABC). Eur J Cancer. 2005; 37: 8

Hayward, JL, Carbone, PP, Heuson, JC. Assessment of response to therapy in advanced breast cancer . Cancer. 1977; 39: 1289-1293 [OpenAIRE] [PubMed] [DOI]

British Breast Group, . Assessment of response to treatment in advanced breast cancer. Lancet. 1974; 2: 38-39 [PubMed] [DOI]

Robertson, JFR, Willsher, PC, Cheung, KL, Blamey, RW. The clinical relevance of static disease ( no change) category for 6 months on endocrine therapy in patients with breast cancer. European Journal of Cancer. 1997; 33: 1774-1779 [PubMed] [DOI]

Cole, MP, Jones, CT, Todd, ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. . Br J Cancer. 1971; 25: 270-275 [OpenAIRE] [PubMed]

Heuson, JC, Engelsman, E, Blonk-Van Der Wijst, J, Maass, H, Drochmans, A, Michel, J, Nowakowski, H, Gorins, A. Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study. Br Med J. 1975; 2: 711-713 [OpenAIRE] [PubMed]

Massidda, B, Mascia, V, Broccia, G, Pasqualucci, S, Deplano, W, Desogus, A, Luxi, G, Pellegrini, A. [Estrogen therapy of advanced breast cancer]. Minerva Med. 1977; 68: 2509-2516 [PubMed]

Beex, L, Pieters, G, Smals, A, Koenders, A, Benraad, T, Kloppenborg, P. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rep. 1981; 65: 179-185 [PubMed]

Ingle, JN, Ahmann, DL, Green, SJ, Edmonson, JH, Bisel, HF, Kvols, LK, Nichols, WC, Creagan, ET, Hahn, RG, Rubin, J, S., F. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer.. N Engl J Med. 1981; 304: 16-21 [PubMed]

Peethambaram, PP, Ingle, JN, Suman, VJ, Hartmann, LC, CL., L. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis.. Breast Cancer Res Treat. 1999; 54: 117-122 [PubMed] [DOI]

Ingle, JN. Estrogen as therapy for breast cancer. Breast Cancer Res. 2002; 4: 133-136 [OpenAIRE] [PubMed] [DOI]

Robertson, JF, Come, SE, Jones, SE, Beex, L, Kaufmann, M, Makris, A, Nortier, JW, Possinger, K, Rutqvist, LE. Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer. 2005; 41: 346-356 [PubMed] [DOI]

Masamura, S, Santner, SJ, Heitjan, DF, Santen, RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab. 1995; 80: 2918-2925 [PubMed] [DOI]

Osipo, C, Gajdos, C, Cheng, D, Jordan, VC. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol. 2005; 93: 249-256 [PubMed] [DOI]

18 references, page 1 of 2
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2006

Efficacy and tolerability of high dose "ethinylestradiol" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents

Robertson John FR; Agrawal Amit; Cheung KL;